SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0000947871-20-000772
Filing Date
2020-10-05
Accepted
2020-10-05 17:17:36
Documents
2
Group Members
ORBIMED CAPITAL GP VI LLCORBIMED CAPITAL LLC

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ss183029_sc13d.htm SC 13D 115287
2 JOINT FILING AGREEMENT ss183029_ex9901.htm EX-99.1 6303
  Complete submission text file 0000947871-20-000772.txt   123223
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D

Mailing Address 200 POWDER MILL ROAD WILMINGTON DE 19803
Business Address 200 POWDER MILL ROAD WILMINGTON DE 19803 (302) 547-3768
Prelude Therapeutics Inc (Subject) CIK: 0001678660 (see all company filings)

IRS No.: 811384762 | State of Incorp.: DE | Fiscal Year End: 0331
Type: SC 13D | Act: 34 | File No.: 005-91717 | Film No.: 201224493
SIC: 2834 Pharmaceutical Preparations